Annexon, Inc. (NASDAQ:ANNX) EVP Ted Yednock Sells 5,408 Shares

Annexon, Inc. (NASDAQ:ANNX) EVP Ted Yednock sold 5,408 shares of the stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $7.41, for a total value of $40,073.28. Following the sale, the executive vice president now owns 71,365 shares of the company’s stock, valued at $528,814.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Ted Yednock also recently made the following trade(s):

• On Thursday, September 19th, Ted Yednock sold 4,500 shares of Annexon stock. The stock was sold at an average price of $7.10, for a total value of $31,950.00.
• On Thursday, September 5th, Ted Yednock sold 5,500 shares of Annexon stock. The shares were sold at an average price of $5.64, for a total value of $31,020.00.
• On Thursday, August 29th, Ted Yednock sold 5,500 shares of Annexon stock. The stock was sold at an average price of $5.95, for a total value of $32,725.00.

Annexon Trading Up 0.1 %

NASDAQ ANNX opened at $7.63 on Friday. Annexon, Inc. has a 1-year low of $1.67 and a 1-year high of $8.40. The firm’s fifty day simple moving average is $6.33 and its 200-day simple moving average is $5.66. The company has a market capitalization of $705.11 million, a PE ratio of -5.19 and a beta of 1.28.

Annexon (NASDAQ:ANNX) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.23) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.23). As a group, analysts predict that Annexon, Inc. will post -0.97 EPS for the current year.

Institutional Trading of Annexon

Large investors have recently added to or reduced their stakes in the business. Bellevue Group AG bought a new stake in Annexon in the first quarter worth $15,647,000. Candriam S.C.A. bought a new stake in shares of Annexon during the 2nd quarter worth about $10,061,000. Vanguard Group Inc. increased its holdings in shares of Annexon by 96.4% during the 1st quarter. Vanguard Group Inc. now owns 3,747,655 shares of the company’s stock valued at $26,871,000 after acquiring an additional 1,839,329 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Annexon by 436.6% in the 2nd quarter. Marshall Wace LLP now owns 1,693,665 shares of the company’s stock valued at $8,299,000 after acquiring an additional 1,378,053 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Annexon by 10,482.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,323,704 shares of the company’s stock worth $9,492,000 after purchasing an additional 1,311,195 shares during the period.

Wall Street Analysts Forecast Growth

ANNX has been the topic of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research report on Monday, September 9th. Needham & Company LLC reissued a “buy” rating and set a $16.00 target price on shares of Annexon in a research note on Tuesday, August 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Annexon in a research report on Tuesday, August 13th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $15.80.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.